Oncotelic Therapeutics (OTCQB: OTLC) and Sapu Nano announced that CEO Vuong Trieu will present the Deciparticle nanomedicine platform at the BIO International Convention 2026 in San Diego. The presentation will highlight the development of ultra-small nanomedicine formulations designed to enable intravenous administration of highly water-insoluble therapeutics. The Deciparticle platform utilizes proprietary amphiphilic polymer systems capable of forming sub-20 nanometer particles for oncology and other therapeutic applications.
The companies plan to showcase development progress across multiple Deciparticle programs, including Sapu006, a polysorbate-free intravenous docetaxel formulation moving into Phase 1b clinical evaluation, and Sapu003, an intravenous everolimus nanomedicine program currently in a global Phase 1b clinical trial. The presentation will also highlight the integration of artificial intelligence and knowledge-organization technologies into formulation development and translational oncology workflows through the PDAOAI platform.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on developing oncology and immunotherapy products to address high-unmet-need cancers and rare pediatric indications. The company's mission is supported by a robust portfolio of inventions created by CEO Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. Oncotelic also leverages its proprietary AI-enabled PDAOAI platform, which supports research, biomarker discovery, and regulatory processes through advanced data analysis and knowledge integration.
Sapu Nano is a biotechnology company developing next-generation nanomedicine platforms to improve drug delivery, enhance therapeutic index, and unlock new clinical potential for established and novel therapeutics, with a primary focus in oncology. The Deciparticle platform is a key part of Sapu Nano's strategy to enable intravenous administration of drugs that are otherwise difficult to formulate due to poor water solubility.
The presentation at BIO 2026 is expected to draw attention from industry stakeholders, as the Deciparticle platform could address a significant challenge in drug development: the delivery of water-insoluble compounds. Many promising therapeutic candidates fail due to solubility issues, and platforms like Deciparticle may expand the range of drugs that can be administered intravenously, potentially improving patient outcomes and treatment options.
For more information, the full press release is available at https://ibn.fm/RUG7m. Additional updates on Oncotelic Therapeutics are available in the company's newsroom at https://ibn.fm/OTLC.
